Investor Relations

Company Profile

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate is SPR720, a novel oral therapy for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections. 

Spero also has tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), designed to be the first broad-spectrum oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. 

Additionally, Spero has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

SPRO (NASDAQ)

Stock Chart

Historical

Analyst Coverage

SEC Filings

Governance & Documents

Governance Documents

Code Of Business Conduct And Ethics
External URL
PDF
Corporate Governance Guidelines
External URL
PDF
Disclosure Controls And Procedures
External URL
PDF
Disclosure Policy
External URL
PDF
Insider Trading Policy
External URL
PDF
Policy Regarding Security Holder Communications
External URL
PDF
Related Person Transaction Policy
External URL
PDF

Committee Charters

Human Capital Management Committee
External URL
PDF
Audit Committee
External URL
PDF
Nominating And Corporate Governance Committee
External URL
PDF

Committee Composition

Email Alerts

Press Releases

Upcoming and Current Events

Past Events

Partnerships

Spero Therapeutics is actively pursuing collaborations with partners for scientific expertise and funding support.

Investor Relations

Stock information, SEC filings, corporate governance, IR resources and more.

Careers

Collaborative. Exciting. Challenging. Stimulating. Committed. Spero Therapeutics was founded in 2013.

About Spero

Led by an executive team with deep experience and world-class scientific talent, Spero is dedicated to delivering differentiated medicines that help patients suffering from serious and life-threatening infections.

Sign up to receive news and announcements.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.